12 recruiting, 6 completed, 3 active not recruiting, 2 unknown. 15 Phase 2, 9 Phase 1, 3 Not applicable, 1 Phase 3, 1 Phase 4.
Follow ER+ Breast Cancer: new trials by email Literature Review of ER+ Breast Cancer trials Research Report on ER+ Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Cancer at High Risk of Recurrence. ER+ Breast Cancer, Breast Cancer | Recruiting | University Hospital, Grenoble | 81 | 2026-05-26 | 2026-10-02 | |
| A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer Neoadjuvant endocrine therapy - Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 176 | 2026-03-13 | 2026-06-04 |
| Breast Re-irradiation After Second Ipsilateral Lumpectomy Intensity modulated radiation therapy (IMRT) - Breast Cancer, Cancer | Not applicable | Recruiting | Youssef Zeidan | 114 | 2025-10-27 | 2025-11-13 |
| Circulating Tumor DNA Elacestrant - ER+ Breast Cancer | Phase 2 | Recruiting | Yale University | 50 | 2025-09-30 | 2026-09-21 |
| A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet - Metastatic Breast Cancer, Breast Cancer Stage I | Phase 1 / Phase 2 | Recruiting | Forward Pharmaceuticals Co., Ltd. | 196 | 2025-06-01 | 2026-01-07 |
| Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer Duloxetine 60 MG, Furosemide 40 mg, Booklet for healthy behaviors - ER+ Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 399 | 2024-12-01 | 2024-11-05 |
| Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. RYZ101, Standard of Care Endocrine Therapy - Metastatic Breast Cancer, HER2-negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | RayzeBio, Inc. | 64 | 2024-07-19 | 2026-10-06 |
| Breast Cancer Evolution During Neoadjuvant Systemic Therapy Breast Cancer, Triple Negative Breast Cancer | Recruiting | Royal Marsden NHS Foundation Trust | 500 | 2024-05-29 | 2026-04-16 | |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies ETX-19477 - Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1 / Phase 2 | Recruiting | 858 Therapeutics, Inc. | 120 | 2024-05-13 | 2026-03-27 |
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications BBI-355, Erlotinib, Futibatinib - Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | Phase 1 | Terminated | Boundless Bio, Inc. | 85 | 2023-03-24 | 2026-08-19 |
| Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression Ipatasertib 300mg, Fulvestrant 500g, Palbociclib 75mg-125mg - Metastatic Breast Cancer, ER+ Breast Cancer | Phase 2 | Active not recruiting | Royal Marsden NHS Foundation Trust | 57 | 2022-12-28 | 2026-04-14 |
| JAB-2485 Activity in Adult Patients With Advanced Solid Tumors JAB-2485 (Aurora A inhibitor) - Solid Tumors, ER+ Breast Cancer | Phase 1 / Phase 2 | Recruiting | Jacobio Pharmaceuticals Co., Ltd. | 102 | 2022-12-20 | 2026-01-09 |
| Tamoxifen Prediction Study in Patients With ER+ Breast Cancer Tamoxifen - ER+ Breast Cancer | Phase 4 | Unknown | Erasmus Medical Center | 100 | 2022-11-01 | 2023-11-01 |
| A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Stereotactic body radiotherapy - Oligometastatic Breast Carcinoma, Breast Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 46 | 2022-09-06 | 2026-10-02 |
| Alcohol and Breast Cancer (ABC) Trial White Wine, Grape Juice - ER+ Breast Cancer, Breast Cancer | Not applicable | Completed | Beth Israel Deaconess Medical Center | 23 | 2022-09-01 | 2024-12-20 |
| A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen - ER+ Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Recruiting | Royal Marsden NHS Foundation Trust | 1100 | 2022-03-30 | 2024-12-05 |
| Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) Entrectinib, Letrozole, Goserelin - Invasive Lobular Breast Carcinoma, ER+ Breast Cancer | Phase 2 | Unknown | Jules Bordet Institute | 65 | 2021-01-14 | 2024-12-04 |
| 4FMFES-PET Imaging of ER+ Advanced Breast Cancers 4FMFES-PET - ER+ Breast Cancer | Phase 2 | Recruiting | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 150 | 2020-11-01 | 2026-07-10 |
| PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer Palbociclib, Avelumab - Triple Negative Breast Cancer, Locally Advanced Breast Cancer | Phase 1 | Active not recruiting | Royal Marsden NHS Foundation Trust | 45 | 2020-08-11 | 2026-08-21 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. Obinutuzumab, naptumomab estafenatox and durvalumab, Naptumomab estafenatox and durvalumab - ER+ Breast Cancer, Ovarian Cancer | Phase 1 | Active not recruiting | NeoTX Therapeutics Ltd. | 120 | 2019-10-10 | 2025-11-28 |
Showing 20 of 25. Sign in to see all of them.
Breast Neoplasms (17) · Triple Negative Breast Neoplasms (6) · Carcinoma, Lobular (2) · Endometrial Neoplasms (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Small Cell Lung Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms, Male (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Drug-Related Side Effects and Adverse Reactions (1)
Breast Diseases (21) · Neoplasms by Site (21) · Skin Diseases (21) · Skin and Connective Tissue Diseases (21) · Neoplasms (20) · Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Breast Neoplasms (4) · Adenocarcinoma (3) · Adnexal Diseases (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Carcinoma, Squamous Cell (2) · Digestive System Diseases (2)
palbociclib (4) · Fulvestrant (3) · exemestane (3) · Letrozole (2) · Tamoxifen (2) · abemaciclib (2) · entinostat (2) · ribociclib (2) · AZD4547 (1) · Anastrozole (1) · Aromatase Inhibitors (1) · Duloxetine Hydrochloride (1) · Erlotinib Hydrochloride (1) · Everolimus (1) · Furosemide (1)
Royal Marsden NHS Foundation Trust (4) · Memorial Sloan Kettering Cancer Center (2) · Syndax Pharmaceuticals (2) · 858 Therapeutics, Inc. (1) · AstraZeneca (1) · Beth Israel Deaconess Medical Center (1) · Boundless Bio, Inc. (1) · Centre de recherche du Centre hospitalier universitaire de Sherbrooke (1) · Erasmus Medical Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Forward Pharmaceuticals Co., Ltd. (1) · Innocrin Pharmaceutical (1) · Jacobio Pharmaceuticals Co., Ltd. (1) · Jules Bordet Institute (1) · Nalagenetics Pte Ltd (1)
United States (11) · United Kingdom (6) · France (4) · Canada (3) · Belgium (2) · China (2) · Czechia (2) · Hungary (2) · Germany (1) · India (1) · Indonesia (1) · Ireland (1) · Israel (1) · Italy (1) · Netherlands (1)
Alicia Okines (2) · Amy Xu, MD, PhD (1) · Baitha P. Maggadani (1) · Daniel McCormick (1) · Denise Yardley, MD (1) · Donal Landers (1) · Eric E Turcotte, MD (1) · Kenneth Mukamal, MD, MPH (1) · Mariya Rozenblit, MD (1) · Nicholas Turner (1) · Petrus de Jong, MD, PhD (1) · Philippe Aftimos, MD (1) · Robert Doebele, MD, PhD (1)
PMID 23650416, PMID 35119530, PMID 35695563, PMID 39789640
2009 (1), K01AA027831 (1)